- Condition: Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab; Procedure: Laser
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2012 - Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical StudyConditions: Aphakia; Cataract
Interventions: Device: Study IOL; Device: Hoya iSert 751; Device: Negatively aspheric IOL
Sponsors: Hoya Surgical Optics, Inc.; Hoya Surgical Optics, Inc.
Recruiting - verified February 2012 - Conditions: Macular Edema; Central Retinal Vein Occlusion
Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified March 2012 - Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular DegenerationConditions: Macular Degeneration; Age-related Maculopathies; Age-related Maculopathy; Maculopathies,Age-related; Maculopathy,Age-related; Retinal Degeneration; Retinal Neovascularization; Eye Diseases
Interventions: Biological: rAAV.sFlt-1; Biological: rAAV.sFlt-1; Other: Control (ranibizumab alone)
Sponsors: Lions Eye Institute, Perth, Western Australia; Lions Eye Institute, Perth, Western Australia; Avalanche Biotechnologies, Inc.
Recruiting - verified December 2011 - Condition: Diabetic Macular Edema
Interventions: Drug: darapladib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified February 2012 - Condition: Myopia
Interventions: Device: galyfilcon A; Device: galyfilcon A plus; Device: lotrafilcon A; Device: polymacon; Other: spectacles
Sponsors: Vistakon; Vistakon
Recruiting - verified November 2011 - Conditions: Diabetes Mellitus; Macular Edema
Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Laser treatment
Sponsors: Bayer; Bayer; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Opioid Dependence
Intervention: Drug: Fentanyl
Sponsors: University of Adelaide; University of Adelaide
Not yet recruiting - verified May 2011 - Conditions: Type 1 Diabetes Mellitus; Retinopathy; Diabetic Nephropathy
Interventions: Drug: Fenofibrate; Drug: Inert lactose placebo
Sponsors: University of Sydney; University of Sydney; Abbott; University of Melbourne; St Vincents Hospital, Melbourne; Melbourne Health; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified March 2011 - Conditions: Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
Intervention: Other: Ranibizumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Dry Eye Syndromes
Interventions: Drug: Formulation 1: Eye Drops New Platform (EDNP) - 1; Drug: Formulation 2: EDNP - 2; Drug: carboxymethylcellulose sodium based artificial tear
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Conditions: Diabetic Retinopathy; Macular Edema
Interventions: Drug: bevacizumab; Drug: dexamethasone
Sponsors: University of Sydney; University of Sydney; National Health and Medical Research Council, Australia
Recruiting - verified February 2012 - Condition: Open-Angle Glaucoma
Interventions: Drug: bimatoprost ophthalmic formulation A, bimatoprost ophthalmic solution 0.03%; Drug: bimatoprost ophthalmic formulation B, bimatoprost ophthalmic solution 0.03%; Drug: bimatoprost ophthalmic formulation C, bimatoprost ophthalmic solution 0.03%
Sponsors: Allergan; Allergan
Recruiting - verified December 2011 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Infant, Premature, Diseases; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Infant, Newborn, Diseases; Infant, Very Low Birth Weight
Interventions: Procedure: Higher oxygen saturation target range (91%-95%); Procedure: Lower oxygen saturation (85%-89%)
Sponsors: University of Sydney; University of Sydney; University of Otago; University of Oxford; University of Pennsylvania; University of California, San Diego
Recruiting - verified August 2011 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Spinal Cord Injury
Interventions: Device: ReJoyce Workstation; Other: Standard Care
Sponsors: University of Melbourne; University of Melbourne; Victorian Neurotrauma Initiative; Lifetime Care and Support Authority (NSW); The University of Western Australia
Recruiting - verified March 2010 - Conditions: Allergic Rhinoconjunctivitis; Chronic Urticaria
Intervention: Drug: Bilastine
Sponsors: Faes Farma, S.A.; Faes Farma, S.A.
Recruiting - verified April 2012 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Join Clinical Trials for Eye Diseases in Australia |
